Physician profile

Nel E Gerig

Urology · Denver, CO

NPI 1912942889

$6,091.39

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$161.37

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Terumo Medical Corporation $5,054.25 2019-2022
Coloplast Corp $444.94 2022-2023 Altis
Astellas Pharma US INC $254.45 2019-2021
Boston Scientific Corporation $90.58 2019-2022
Arbor Pharmaceuticals, INC. $86.21 2019-2020
Dentsply Ih INC. $47.66 2019-2020
Si-Bone, INC. $33.19 2019
Abbott Laboratories $19.19 2020
Medtronic USA, INC. $17.43 2020
Axonics, INC. $17.37 2021
Medtronic, INC. $13.34 2021
Pfizer INC. $12.78 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nel E Gerig

$6,091.39

in general payments reported 2019-2025

Years
2019-2023
Top company
Terumo Medical Corporation

https://glasscript.com/doctor/86306/nel-e-gerig

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.